Vicore Pharma Holding
ISIN: SE0007577895 | Ticker: VICO | LEI: 549300KTNBPTZLF01130
Country: Sweden
We are an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected.
Patients with severe lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. We appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds.
2000
Served areaWorldwide
HeadquartersKronhusgatan 11, 41105 Göteborg – Sweden
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 451,168,000.00 | 338,007,000.00 |
| Noncurrent Assets | N/A | 73,237,000.00 | 68,217,000.00 |
| Property Plant And Equipment | N/A | 84,000.00 | 54,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | 67,427,000.00 | 68,100,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 5,409,000.00 | 0.00 |
| Current Assets | N/A | 377,931,000.00 | 269,790,000.00 |
| Other Current Receivables | N/A | 1,417,000.00 | 2,180,000.00 |
| Cash and cash equivalents | 248,618,000.00 | 294,199,000.00 | 256,803,000.00 |
| Current Investments | N/A | 77,281,000.00 | 4,940,000.00 |
| Equity And Liabilities | N/A | 451,168,000.00 | 338,007,000.00 |
| Equity | 354,513,000.00 | 383,316,000.00 | 289,083,000.00 |
| Issued Capital | N/A | 35,880,000.00 | 40,924,000.00 |
| Retained Earnings | N/A | -674,230,000.00 | -962,652,000.00 |
| Additional Paidin Capital | N/A | 1,021,666,000.00 | 1,210,811,000.00 |
| Liabilities | N/A | 67,852,000.00 | 48,924,000.00 |
| Noncurrent Liabilities | N/A | 2,130,000.00 | 2,505,000.00 |
| Other Longterm Provisions | N/A | 600,000.00 | 1,600,000.00 |
| Deferred Tax Liabilities | N/A | 1,210,000.00 | 905,000.00 |
| Current Liabilities | N/A | 65,722,000.00 | 46,419,000.00 |
| Other Shortterm Provisions | N/A | 152,000.00 | 127,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 23,984,000.00 | 23,495,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | 40,139,000.00 | 18,221,000.00 |
| Current Tax Liabilities Current | N/A | 335,000.00 | 760,000.00 |
| Other Current Liabilities | N/A | 1,112,000.00 | 3,751,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Profit Loss From Operating Activities | -294,818,000.00 | -290,725,000.00 |
| Finance Income | 646,000.00 | 2,395,000.00 |
| Finance Costs | 2,563,000.00 | 476,000.00 |
| Profit Loss Before Tax | -296,735,000.00 | -288,806,000.00 |
| Income Tax Expense Continuing Operations | -254,000.00 | -384,000.00 |
| Profit (loss) | -296,481,000.00 | -288,422,000.00 |
| Profit Loss Attributable To Owners Of Parent | -296,481,000.00 | -288,422,000.00 |
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | -296,481,000.00 | -288,422,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 8,000.00 | 8,000.00 |
| Interest Received Classified As Operating Activities | N/A | 483,000.00 | 1,194,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -265,171,000.00 | -299,919,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 3,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -7,000,000.00 | 74,000,000.00 |
| Proceeds From Issuing Shares | N/A | 336,000,000.00 | 200,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 239,000.00 | 252,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 318,183,000.00 | 187,040,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 46,012,000.00 | -38,879,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -431,000.00 | 1,483,000.00 |
| Cash and cash equivalents | 248,618,000.00 | 294,199,000.00 | 256,803,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 08.06.22 | Jacob Uno Stanley Gunterberg | Other | Buy | SEK 220,800.00 |
| 03.06.22 | Johannes Schikan | Other | Buy | SEK 119,880.00 |
| 03.06.22 | Sara Malcus | Other | Buy | SEK 87,495.30 |
| 01.06.22 | Maarten Kraan | Other | Buy | SEK 121,152.50 |
| 16.09.21 | Carl Johan Dalsgaard | Other | Other | SEK 0.00 |
| 06.10.20 | Carl Johan Dalsgaard | Other | Other | SEK 0.00 |
| 04.06.20 | Heidi Hunter | Other | Buy | SEK 0.00 |
SE0007577895
LEI549300KTNBPTZLF01130
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.